Under construction – not a live service
Sign in

NCT07914907Recruiting

GenAI-Assisted Rheumatoid Arthritis Bone Erosion Risk Assessment and DMARD Selection

Prospective Evaluation of Generative AI-Augmented Clinical Decision-Making for Rheumatoid Arthritis Bone Erosion Risk (RABER) Assessment and DMARD Selection in Routine Care

Source: ClinicalTrials.gov · Last updated 4 Nov 2026

Next steps

Brief summary (registry, in English)

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by progressive joint damage and bone erosion. Accurate assessment of RA bone erosion risk (RABER) and appropriate disease-modifying antirheumatic drug (DMARD) selection are critical to preventing irreversible disability. Recent advances in generative artificial intelligence (GenAI), particularly large language models (LLMs), enable integration of heterogeneous clinical data and may improve clinical decision-making. However, there is limited real-world evidence (RWE) evaluating whether GenAI can meaningfully augment physician decision-making in routine care. This prospective, single-arm, nonrandomized interventional study evaluates the feasibility and impact of GenAI-assisted clinical decision support on physician assessment of rheumatoid arthritis bone erosion risk and disease-modifying antirheumatic drug selection in routine inpatient care. Treating physicians document their initial risk assessments and treatment decisions before reviewing patient-specific GenAI reports and subsequently record their assessments and decisions after reviewing the reports. The study evaluates changes in physician clinical decision-making within a learning health system framework. Final treatment decisions remain under the responsibility of the treating physicians. The study does not evaluate long-term patient clinical outcomes.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
100 (estimated)
First submitted
21 Oct 2026
Start date
1 Mar 2026
Primary completion date
31 Oct 2026
Lead sponsor
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
NCT number
NCT07914907

What you commit to

  • Study type: Interventional
  • Planned participants: 100
  • From 1 Mar 2026 to the primary completion date, 31 Oct 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study design.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • Patients subsequently determined not to have RA
  • Incomplete clinical data preventing risk or treatment assessment

Who the study is looking for

  • Newly diagnosed RA patients meeting American College of Rheumatology / European League Against Rheumatism 2010 classification criteria
  • Consecutive inpatients admitted during study period

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
Guang'anmen Hospital of China Academy of Chinese Medical SciencesBeijingChinaRecruiting

Are you the coordinator? Confirm the details

This page is information, not medical advice. Discuss any trial with your doctor.

Under construction, not live – GenAI-Assisted Rheumatoid Arthritis Bone Erosion Risk Assessment and DMARD Selection (NCT07914907) – Frontlight Research